Cencora has made headlines with its announcement on March 10, 2025, detailing plans for strategic acquisitions and investments in technology infrastructure, aiming to drive future growth.

Have you been paying attention to shares of Cencora (COR)? Shares have been on the move with the stock up 6.2% over the past month. The stock hit a new 52-week high of $262.56 in the previous session.

Cencora (NYSE:COR) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

Wells Fargo raised the firm’s price target on Cencora (COR) to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is updating its model following Cencora’s results and ...

Cencora has a 12 month low of $214.77 and a 12 month high of $263.70. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

With a market cap of $50.5 billion, Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a global healthcare solutions provider specializing in pharmaceutical distribution and related services.

In a recent 8-K filing with the Securities and Exchange Commission, Cencora, Inc., a Delaware-based company in the wholesale drug industry and a prominent player in Healthcare Providers & Services ...

Cencora Price Performance COR opened at $258.09 on Friday. The stock has a fifty day simple moving average of $247.59 and a two-hundred day simple moving average of $239.09. The company has a ...

In a recent 8-K filing with the Securities and Exchange Commission, Cencora, Inc., a Delaware-based company in the wholesale drug industry and a prominent player in Healthcare Providers & Services ...